Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADVM NASDAQ:CHRS NASDAQ:INBX NASDAQ:MESO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADVMAdverum Biotechnologies$4.36$4.30$1.78▼$5.75$96.26M0.87452,470 shsN/ACHRSCoherus Oncology$1.48-0.7%$1.73$0.71▼$2.62$229.83M1.011.39 million shs1.37 million shsINBXInhibrx Biosciences$109.51+3.5%$89.15$12.24▼$155.29$1.55B3.88738,687 shs303,476 shsMESOMesoblast$14.55-0.6%$15.06$9.88▼$21.50$1.90B2.09160,995 shs140,140 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADVMAdverum Biotechnologies0.00%0.00%0.00%0.00%+97.29%CHRSCoherus Oncology-0.67%-13.45%-25.25%-9.20%+85.00%INBXInhibrx Biosciences+3.51%+0.79%+24.12%+34.24%+778.19%MESOMesoblast-0.61%+0.76%-11.60%-14.61%+25.97%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADVMAdverum Biotechnologies$4.36$4.30$1.78▼$5.75$96.26M0.87452,470 shsN/ACHRSCoherus Oncology$1.48-0.7%$1.73$0.71▼$2.62$229.83M1.011.39 million shs1.37 million shsINBXInhibrx Biosciences$109.51+3.5%$89.15$12.24▼$155.29$1.55B3.88738,687 shs303,476 shsMESOMesoblast$14.55-0.6%$15.06$9.88▼$21.50$1.90B2.09160,995 shs140,140 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADVMAdverum Biotechnologies0.00%0.00%0.00%0.00%+97.29%CHRSCoherus Oncology-0.67%-13.45%-25.25%-9.20%+85.00%INBXInhibrx Biosciences+3.51%+0.79%+24.12%+34.24%+778.19%MESOMesoblast-0.61%+0.76%-11.60%-14.61%+25.97%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADVMAdverum Biotechnologies 2.00Hold$10.50140.83% UpsideCHRSCoherus Oncology 2.75Moderate Buy$8.67485.59% UpsideINBXInhibrx Biosciences 2.33Hold$150.0036.97% UpsideMESOMesoblast 2.33HoldN/AN/ACurrent Analyst Ratings BreakdownLatest MESO, INBX, ADVM, and CHRS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2026CHRSCoherus Oncology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C-) ➝ Hold (C)5/11/2026CHRSCoherus Oncology GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$12.005/11/2026CHRSCoherus Oncology GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$12.004/24/2026INBXInhibrx Biosciences Lifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/22/2026CHRSCoherus Oncology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C-)4/21/2026MESOMesoblast Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/9/2026INBXInhibrx Biosciences Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold4/8/2026CHRSCoherus Oncology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)4/8/2026INBXInhibrx Biosciences Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$150.00(Data available from 5/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADVMAdverum BiotechnologiesN/AN/AN/AN/A$3.40 per shareN/ACHRSCoherus Oncology$42.17M5.41N/AN/A$0.51 per share2.90INBXInhibrx Biosciences$1.30M1,235.78N/AN/A($1.43) per share-76.58MESOMesoblast$17.20M109.51N/AN/A$4.67 per share3.12Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADVMAdverum Biotechnologies-$130.93M-$8.58N/AN/AN/AN/A-3,476.17%-152.07%N/ACHRSCoherus Oncology$168.02M$1.670.89N/AN/A397.30%-198.90%-46.65%8/6/2026 (Estimated)INBXInhibrx Biosciences-$140.05M-$8.39N/AN/AN/AN/A-563.90%-72.32%N/AMESOMesoblast-$102.14M-$0.54N/AN/AN/AN/AN/AN/AN/ALatest MESO, INBX, ADVM, and CHRS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026INBXInhibrx Biosciences-$1.6750-$2.15-$0.4750-$2.15N/AN/A5/11/2026Q1 2026CHRSCoherus Oncology-$0.2633-$0.25+$0.0133-$0.28$14.22 million$12.31 million3/19/2026Q4 2025INBXInhibrx Biosciences-$2.08-$2.11-$0.03-$2.11N/AN/A3/9/2026Q4 2025CHRSCoherus Oncology-$0.31-$0.34-$0.03-$0.31$14.09 million$12.75 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthADVMAdverum BiotechnologiesN/AN/AN/AN/AN/ACHRSCoherus OncologyN/AN/AN/AN/AN/AINBXInhibrx BiosciencesN/AN/AN/AN/AN/AMESOMesoblastN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADVMAdverum BiotechnologiesN/A0.650.65CHRSCoherus Oncology0.471.561.52INBXInhibrx Biosciences12.586.466.46MESOMesoblast0.101.581.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADVMAdverum Biotechnologies48.17%CHRSCoherus Oncology72.82%INBXInhibrx Biosciences82.46%MESOMesoblast1.43%Insider OwnershipCompanyInsider OwnershipADVMAdverum Biotechnologies6.00%CHRSCoherus Oncology8.08%INBXInhibrx BiosciencesN/AMESOMesoblast18.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADVMAdverum Biotechnologies19022.08 million20.75 millionOptionableCHRSCoherus Oncology330154.25 million141.79 millionOptionableINBXInhibrx Biosciences16614.67 millionN/AOptionableMESOMesoblast80129.46 million105.12 millionOptionableMESO, INBX, ADVM, and CHRS HeadlinesRecent News About These Companies3 reasons why this ASX biotech stock could double in valueMay 11, 2026 | fool.com.auHow Completion Of RMAT Phase 3 Enrollment At Mesoblast (ASX:MSB) Has Changed Its Investment StoryMay 2, 2026 | finance.yahoo.comMesoblast (NASDAQ:MESO) Stock Price Crosses Above 50 Day Moving Average - Time to Sell?May 1, 2026 | marketbeat.comMesoblast Ramps Up Ryoncil Sales, Advances Late-Stage Cell Therapy PipelineApril 29, 2026 | tipranks.comMesoblast Reports Ryoncil® Net Revenues of US$30.3m and Improved Net Operating Cash Spend for the Quarter to US$4.1 MillionApril 29, 2026 | globenewswire.comA big milestone for this ASX biotech. Here's why the share price is movingApril 29, 2026 | msn.comMesoblast shares in focus after key phase 3 milestone for low back painApril 29, 2026 | msn.comMesoblast Ltd (MESO): Secure Exclusive Rights to a Vital PlatformApril 29, 2026 | finance.yahoo.comAssessing Mesoblast’s Valuation After Recent Share Price Weakness And Conflicting Growth SignalsApril 29, 2026 | finance.yahoo.comMesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back PainApril 28, 2026 | globenewswire.comMesoblast Hits Phase 3 Recruitment Milestone in Chronic Back Pain PushApril 28, 2026 | tipranks.comMesoblast (NASDAQ:MESO) Shares Cross Above Fifty Day Moving Average - Here's WhyApril 23, 2026 | marketbeat.comWhy Mesoblast Limited (MESO) is One of the Best Low Priced Biotech Stocks to Invest inApril 19, 2026 | finance.yahoo.comMesoblast Limited (MESO), One of the Best Long-Term ASX Stocks To Buy Right Now; See WhyApril 19, 2026 | finance.yahoo.comMesoblast Limited (MESO), One of the Best Long-Term ASX Stocks To Buy Right Now; See WhyApril 19, 2026 | insidermonkey.comMesoblast Issues 3.28 Million New Shares on Option ConversionsApril 18, 2026 | theglobeandmail.comMesoblast Reports Lapse of 723,666 Options, Reducing Potential DilutionApril 18, 2026 | theglobeandmail.comMesoblast Issues 815,000 Unquoted Options Under Employee Incentive SchemeApril 18, 2026 | theglobeandmail.comMesoblast Secures CAR Platform to Sharpen Targeting of Cell TherapiesApril 16, 2026 | theglobeandmail.comMesoblast Limited - Depositary Receipt (MESO) price target increased by 69.97% to 26.06April 16, 2026 | msn.comWhy Evolution Mining, Mesoblast, Nufarm, and Virgin Australia shares are storming higher todayApril 15, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMESO, INBX, ADVM, and CHRS Company DescriptionsAdverum Biotechnologies NASDAQ:ADVMAdverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.Coherus Oncology NASDAQ:CHRS$1.48 -0.01 (-0.67%) Closing price 05/19/2026 04:00 PM EasternExtended Trading$1.47 -0.01 (-0.68%) As of 05/19/2026 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.Inhibrx Biosciences NASDAQ:INBX$109.51 +3.71 (+3.51%) Closing price 05/19/2026 04:00 PM EasternExtended Trading$109.42 -0.09 (-0.08%) As of 05/19/2026 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.Mesoblast NASDAQ:MESO$14.55 -0.09 (-0.61%) Closing price 05/19/2026 04:00 PM EasternExtended Trading$14.55 0.00 (0.00%) As of 05/19/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas HIVE Weaponizes Power for an AI Pivot Why Home Depot’s Sell-Off Could Become a Huge Opportunity Brady Corp Wires Up a Massive AI-Powered Breakout AAPL: Forget the iPhone—Services Will Drive the Next Phase of Growth Nebius Group Pulls Back 9% After a Downgrade Despite Strong Earnings A Deep Dive Into NVIDIA’s Latest Portfolio Moves The $132 Billion Infrastructure Pivot You Might Have Missed The Pentagon's AI Pivot Supercharges Defense Stocks Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
